全文获取类型
收费全文 | 51552篇 |
免费 | 4681篇 |
国内免费 | 102篇 |
专业分类
耳鼻咽喉 | 432篇 |
儿科学 | 1343篇 |
妇产科学 | 1196篇 |
基础医学 | 7307篇 |
口腔科学 | 955篇 |
临床医学 | 5669篇 |
内科学 | 10409篇 |
皮肤病学 | 657篇 |
神经病学 | 4865篇 |
特种医学 | 1382篇 |
外国民族医学 | 3篇 |
外科学 | 6978篇 |
综合类 | 1108篇 |
一般理论 | 57篇 |
预防医学 | 4958篇 |
眼科学 | 1331篇 |
药学 | 4382篇 |
1篇 | |
中国医学 | 65篇 |
肿瘤学 | 3237篇 |
出版年
2023年 | 270篇 |
2021年 | 960篇 |
2020年 | 582篇 |
2019年 | 965篇 |
2018年 | 1018篇 |
2017年 | 805篇 |
2016年 | 887篇 |
2015年 | 1042篇 |
2014年 | 1469篇 |
2013年 | 2159篇 |
2012年 | 3061篇 |
2011年 | 3215篇 |
2010年 | 1841篇 |
2009年 | 1574篇 |
2008年 | 2711篇 |
2007年 | 3003篇 |
2006年 | 2979篇 |
2005年 | 3015篇 |
2004年 | 2840篇 |
2003年 | 2654篇 |
2002年 | 2439篇 |
2001年 | 915篇 |
2000年 | 873篇 |
1999年 | 846篇 |
1998年 | 618篇 |
1997年 | 507篇 |
1996年 | 473篇 |
1995年 | 500篇 |
1994年 | 426篇 |
1993年 | 409篇 |
1992年 | 672篇 |
1991年 | 605篇 |
1990年 | 567篇 |
1989年 | 553篇 |
1988年 | 513篇 |
1987年 | 511篇 |
1986年 | 451篇 |
1985年 | 517篇 |
1984年 | 467篇 |
1983年 | 394篇 |
1982年 | 413篇 |
1981年 | 350篇 |
1980年 | 328篇 |
1979年 | 397篇 |
1978年 | 351篇 |
1977年 | 270篇 |
1976年 | 297篇 |
1974年 | 327篇 |
1973年 | 330篇 |
1972年 | 269篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
5.
James A. Akingbasote Alison J. Foster Ian Wilson Sunil Sarda Huw B. Jones J. Gerry Kenna 《Archives of toxicology》2016,90(4):853-862
Hepatic NADPH-cytochrome P450 oxidoreductase null (HRN?) mice exhibit normal hepatic and extrahepatic biotransformation enzyme activities when compared to wild-type (WT) mice, but express no functional hepatic cytochrome P450 activities. When incubated in vitro with [14C]-diclofenac, liver microsomes from WT mice exhibited extensive biotransformation to oxidative and glucuronide metabolites and covalent binding to proteins was also observed. In contrast, whereas glucuronide conjugates and a quinone-imine metabolite were formed when [14C]-diclofenac was incubated with HRN? mouse liver, only small quantities of P450-derived oxidative metabolites were produced in these samples and covalent binding to proteins was not observed. Livers from vehicle-treated HRN? mice exhibited enhanced lipid accumulation, bile duct proliferation, hepatocellular degeneration and necrosis and inflammatory cell infiltration, which were not present in livers from WT mice. Elevated liver-derived alanine aminotransferase, glutamate dehydrogenase and alkaline phosphatase activities were also observed in plasma from HRN? mice. When treated orally with diclofenac for 7 days, at 30 mg/kg/day, the severities of the abnormal liver histopathology and plasma liver enzyme findings in HRN? mice were reduced markedly. Oral diclofenac administration did not alter the liver histopathology or elevate plasma enzyme activities of WT mice. These findings indicate that HRN? mice are valuable for exploration of the role played by hepatic P450s in drug biotransformation, but poorly suited to investigations of drug-induced liver toxicity. Nevertheless, studies in HRN? mice could provide novel insights into the role played by inflammation in liver injury and may aid the evaluation of new strategies for its treatment. 相似文献
6.
7.
8.
9.
Clare Delany PhD Master MSPT BAppSc Ian Edwards PhD Grad Dip PT BAppSc Caroline Fryer PhD Grad Dip BAppSc 《Physiotherapy theory and practice》2019,35(7):663-676
The profile and reach of physiotherapy has expanded in areas of extended scope of practice, and broader engagement with population needs beyond the individual treatment encounter. These changes raise increasingly complex ethical challenges evidenced by growth in physiotherapy-based ethics studies and discussions. This paper examines how a broad cross section of Australian physiotherapists perceive, interpret, and respond to ethical challenges in their work contexts and how professional codes of conduct are used in their practice. Using an interpretive qualitative methodology, purposive sampling of 88 members of national clinical special interest groups were recruited for focus group discussions. Narrative-based and thematic data analysis identified ethical challenges as emerging from specific clinical contexts, and influenced by health organizations, funding policies, workplace relationships, and individually held perspectives. Five themes were developed to represent these findings: (1) the working environment, (2) balancing diverse needs and expectation, (3) defining ethics, (4) striving to act ethically, and (5) talking about ethics. The results portray a diverse and complex ethical landscape where therapists encounter and grapple with ethical questions emerging from the impact of funding models and policies affecting clinical work, expanding boundaries and scope of practice and changing professional roles and relationships. Codes of conduct were described as foundational ethical knowledge but not always helpful for “in the moment” ethical decision-making. Based on this research, we suggest how codes of conduct, educators, and professional associations could cultivate and nurture ethics capability in physiotherapy practitioners for these contemporary challenges. 相似文献
10.